1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jenkem Technology Co., Ltd. Class A

Jenkem Technology Co., Ltd. Class A

SSSE:688356
80.17
CNY
-6.39
(-7.38%)
4.67BMarket Cap
Oct 30Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.68
1.71
2.26
2.99
3.72
5.85
6.78
4.85
3.73
5.26
- -
Basic EPS, GAAP
0.09
0.47
0.81
1.37
1.71
2.93
3.11
1.92
0.49
1.02
- -
Free Cash Flow per Basic Share
0.14
0.29
0.58
0.65
1.19
-0.78
-0.45
0.6
1.51
0.39
- -
Dividend per Share
0.44
0.11
0.17
0.22
- -
0.43
0.88
0.93
0.57
0.15
- -
Book Value per Share
2.73
3.1
3.75
4.9
14.27
17.53
20.32
21.12
20.89
21.72
21.42
Tangible Book Value per Share
2.63
2.72
3.37
4.53
13.99
17.17
19.97
20.79
20.22
20.35
20.82
Basic Weighted Avg Shares
44
45
45
45
50
60
60
60
61
60
61
Sales/Revenue/Turnover
74
77
101
134
187
351
407
292
227
318
- -
Operating Margin (%)
10.82
35.41
43.18
49.06
56.38
53.08
50.07
44.56
16.34
23.59
- -
Depreciation Expense
5
5
6
7
9
16
23
30
46
47
- -
Net Income, GAAP
4
21
36
62
86
176
187
116
30
62
- -
Effective Tax Rate (%)
59.99
16.57
14.76
12.83
15.2
13.05
10.03
8.29
8.67
10.79
- -
Profit Margin (%)
5.37
27.46
35.82
45.82
45.91
50.05
45.88
39.62
13.14
19.39
- -
Working Capital
45
48
77
120
741
731
710
680
626
647
638
LT Debt
- -
- -
- -
- -
6
5
2
1
5
4
4
Total Equity
123
140
169
220
856
1,052
1,225
1,280
1,267
1,318
1,299
Return on Invested Capital (%)
- -
15.11
22.58
30.43
15.58
18.26
16.41
9.25
2.41
4.8
- -
Return on Capital (%)
- -
15.92
22.93
31.51
15.76
18.28
16.35
9.22
2.35
4.76
- -
Return on Common Equity (%)
- -
16.13
23.52
31.64
15.92
18.43
16.41
9.24
2.34
4.77
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
4
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
61
Market Capitalization
4,985
5,605
4,675

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
732
702
697
Cash, Cash Equivalents & STI
535
525
477
Accounts Receivable, Net
105
85
123
Inventories
78
81
81
Total Current Liabilities
85
67
59
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.35%
4.01%
Free Cash Flow
- -
-74.6%
-74.26%
Net Income, GAAP
- -
21.19%
106.78%
Sales/Revenue/Turnover
- -
18.75%
40.13%
Total Cash Common Dividend
- -
8,656.34%
-73.88%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
65
64
57
41
227
2025
69
61
- -
107
318
2026
79
106
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.22
0.08
-0.05
0.49
2025
0.2
0.17
- -
0.35
1.02
2026
0.37
-0.32
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.43
0.14
- -
0.57
2025
- -
- -
- -
- -
0.15
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xuan Zhao
Full Time Employees
304
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building C-1, Beilingdi Beijing BE China 100192
IPO Date
Aug 26, 2020
Website
jenkem.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jenkem Technology Co., Ltd. (688356.SS) researches, develops, manufactures, and sells medical and pharmaceutical polyethylene glycol (PEG) derivatives and related products in China and internationally. The company offers a comprehensive range of high-purity, low-polydispersity PEG products, including branched, linear, homobifunctional, heterobifunctional, multi-arm homofunctional, multi-arm heterofunctional, monodisperse/discrete, and biodegradable PEG derivatives; PEG co-polymers such as PEG-PLGA, PEG-PLA, and PEG-PCL; lipids for lipid nanoparticle (LNP) delivery systems, including ALC-0315, ALC-0159 (M-DTDAM-2000), M-DMG-2000, and SM-102, with four products registered as pharmaceutical excipients in China; PEGs for click chemistry and targeted protein degradation like PROTAC and LYTAC linkers; and PEG fatty acids and side chains, available in research, GMP, and commercial scales up to 100kg batches. Founded in 2001 and headquartered in Beijing's Zhongguancun Science Park, Jenkem Technology operates manufacturing facilities in Tianjin (15,000 sqm industrial base, National Green Factory 2024 award winner), Liaoning (new high-capacity plant operational since Q4 2023 for PEG raw materials and GMP production), and a U.S. office in Plano, Texas for international sales; it supports over 1,200 domestic and global customers in pharmaceuticals, biotech, medical devices, and diagnostics, with products enabling 20 commercial drugs/vaccines and 80+ clinical projects as of 2024. Recent developments include expansion of manufacturing capacity in 2024 with the new Liaoning facility boosting PEG raw material production to 10kg-1000kg batches and GMP output by 6-10 times; advancements in LNP lipids and discrete PEG linkers for ADCs and degraders; 114 active patents and 107 pending as of May 2025; and active participation in 2025 industry events like LNP Summit, BIO China, and ADC Summit, alongside custom PEGylation services for proteins, peptides, oligonucleotides, and small molecules.